Relday is a proprietary, once-monthly subcutaneous formulation of risperidone for treating schizophrenia. Zogenix expects to begin a multi-dose clinical trial to provide steady-state pharmacokinetic and safety data in the second half of 2014.
Risperidone is one of the most widely prescribed medications used to treat the symptoms of schizophrenia in adults and teenagers 13 years of age and older. The global long-acting injectable antipsychotic market was approximately $2 billion in 2011, with currently approved products using a 21-gauge or larger needle for intramuscular injections. The leading product in the category requires twice-a-month dosing and drug reconstitution prior to use. The combined market for oral and injectable antipsychotic products was estimated at more than $17 billion in 2011.
If approved, Relday will be the first subcutaneous antipsychotic product that allows for once-monthly dosing. In July 2011, we licensed from DURECT exclusive global rights to develop and commercialize this proprietary formulation which utilizes DURECT’s SABER® depot technology. We believe that Relday will offer an improved pharmacokinetic profile, significant reduction in injection volume and a simplified dosing regimen due to DURECT’s SABER controlled-release formulation technology.
Relday™ is a trademark of Zogenix, Inc.
SABER® is a trademark of DURECT.